# Magnetic Resonance Imaging (MRI) to Predict Outcomes of Pancreatic Ductal Adenocarcinoma (PDAC)

> **NCT04700488** · NA · SUSPENDED · sponsor: **Cedars-Sinai Medical Center** · enrollment: 36 (estimated)

## Conditions studied

- PDAC - Pancreatic Ductal Adenocarcinoma

## Interventions

- **DIAGNOSTIC_TEST:** 6D-MRI

## Key facts

- **NCT ID:** NCT04700488
- **Lead sponsor:** Cedars-Sinai Medical Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2022-05-19
- **Primary completion:** 2026-01
- **Final completion:** 2026-01
- **Target enrollment:** 36 (ESTIMATED)
- **Why stopped:** Cedars-Sinai Cancer Center Protocol Review and Monitoring Committee has requested several protocol modifications and clarifications regarding study outcomes and completion of data entry for subjects who exited the study. Changes are in the process.
- **Last updated:** 2025-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04700488

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04700488, "Magnetic Resonance Imaging (MRI) to Predict Outcomes of Pancreatic Ductal Adenocarcinoma (PDAC)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04700488. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*